Trevigen-DNA Damage細胞損傷分析系列
PARP in vivo Pharmacodynamic Assay II
PARP catalyzes the NAD-dependent addition of poly (ADP-ribose) (PAR) onto itself and adjacent nuclear proteins. Furthermore, polymorphisms in the PARP-1 gene correspond to disease predisposition, and variation in PARP activity might have an impact on the effects of PARP inhibitors in clinical settings. To address the need to monitor PARP activity among different individuals, and within cells, Trevigen's improved validated PARP in vivo Pharmacodynamic Assay II measures net PAR levels in cellular extracts and has been used to document differences in PAR levels among tumor lysates from different tissues, organs and xenografts. The HT PARP in vivo Pharmacodynamic Assay II employs a purified, pre-coated monoclonal PAR antibody as the capture agent, and anti-PAR polyclonal rabbit antibody as the detecting agent.
PARP產品特點
|
· Fewer user steps
· Pre-coated 96 well capture antibody plates
· High signal to noise ratio
· Detection sensitivity of 2 pg/ml of PAR
· Broad linear dynamic range to 1,000 pg/ml
· Reduced inter-assay variability
· Commercially available validated assay that measures drug action on PARP in both in vivo and in vitro settings
| ||
PARP產品應用:
|
· Quantification of PAR in peripheral blood mononuclear cells, tissue culture cells, and tumor lysates from different tissues, organs and xenografts.
· Monitoring the efficacy of PARP inhibitors on PAR formation in vivo.
· Verifying observations of enhanced cancer cell cytotoxicity arising from PARP inhibitor/anticancer drug combination therapy.
· Facilitating development of PARP and PARG targeted therapeutics
| ||
Components:
|
Part #
|
Component
|
Size
|
4520-096-01
|
PAR Standard, 25 pg/μl
|
5 x 20 μl
| |
4520-096-02
|
Sample Buffer
|
20 ml
| |
4520-096-03
|
PAR Polyclonal Detecting Antibody
|
30 μl
| |
4520-096-04
|
Goat anti-Rabbit IgG-HRP
|
30 μl
| |
PARP PeroxyGlow™ A
|
6 ml
| ||
PARP PeroxyGlow™ B
|
6 ml
| ||
4520-096-05
|
Cell Lysis Reagent
|
30 ml
| |
4520-096-06
|
DNase 1, 2 Units/μl
|
60 μl
| |
4520-096-07
|
100X Magnesium Cation
|
500 μl
| |
4520-096-P
|
Pre-coated white 96-stripwell plate, and 5 sealers
|
1 plate
| |
4520-096-08
|
Jurkat Cell Lysate Standard Control, Low
|
600 μl
| |
4520-096-09
|
Jurkat Cell Lysate Standard Control, Medium
|
600 μl
| |
4520-096-10
|
Jurkat Cell Lysate Standard Control, High
|
600 μl
| |
4520-096-11
|
Antibody Diluent
|
15 ml
| |
4520-096-12
|
20% (w/v) SDS
|
1 ml
| |
Storage:
|
Components are stored at -80°C , -20°C , 4°C , and room temperature
| ||
References:
|
1. Virag, L., and Szabo, C. 2002. The therapeutic potential of Poly(ADP-Ribose) Polymerase inhibitors. Pharmacological Reviews 54:375-429.
2. Thiemermann, C., J. Bowes, F.P. Myint, and J.R. Vane. 1997. Inhibition of the activity of poly(ADP-ribose) synthase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci USA 94:679-83. 3. Curtin NJ. 2005. PARP inhibitors for cancer therapy. Expert Rev Mol Med 7:1-20. 4. Kinders JK, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, Parchment RE, and the National Cancer Institute Phase 0 Clinical Trials Team. 2008. Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) polymerase in Tumor Biopsies of Mouse Xenografts. Clin Cancer Res 14:6877-85. | ||
沒有留言:
張貼留言